Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-07-18Clinical Trial Update: Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy [Phase 2]
A Phase 2 clinical trial evaluating the safety of combining pentoxifylline and celecoxib in patients with grand-mal epilepsy treated with ph…
-
FDA approval · 2024-07-16FDA Approved: TOPIRAMATE — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approves Glenmark's Original Application for Topiramate, a generic anticonvulsant. Topiramate is approved for certain seizure disorders …
-
CLINICAL_TRIALS research · 2024-07-16Clinical Trial Update: SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom
ClinicalTrials.gov reports a UK natural history study of SCN1A-related epilepsies that is currently recruiting to better characterize diseas…
-
FDA approval · 2024-07-15FDA Approved: CLOBAZAM — Supplemental Application (Novadoz Pharmaceuticals LLC)
The FDA approved a supplemental application for CLOBAZAM filed by Novadoz Pharmaceuticals LLC.
-
FDA label_change · 2024-07-15FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for divalproex sodium submitted by Sun Pharmaceutical Industries, Inc. The action pertains to labeli…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-07-12FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Div of Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2024-07-12Clinical Trial Update: Feasibility Study on LITT for Medical Refractory Epilepsy [NA]
This update reports the termination of Monteris Medical's feasibility study evaluating laser interstitial thermal therapy (LITT) for medical…
-
CLINICAL_TRIALS research · 2024-07-12Clinical Trial Update: The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children
This clinical trial update reports on the use of levetiracetam for managing status epilepticus in children and notes that the study is curre…
-
FDA approval · 2024-07-10FDA Approved: CLOBAZAM — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approved a supplemental application for CLOBAZAM (clobazam), a generic seizure medication manufactured by Taro Pharmaceuticals U.S.A., I…
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: Effects of Levetiracetam Monotherapy on Various Hematological Parameters in Adult Patients Suffering of Epilepsy
This clinical trial update from Assiut University examines whether levetiracetam monotherapy affects hematologic parameters in adults with e…
-
FDA approval · 2024-07-05FDA Approved: LEVETIRACETAM — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for Levetiracetam from Micro Labs Limited.
-
FDA approval · 2024-07-03FDA Approved: LEVETIRACETAM — Supplemental Application (Baxter Healthcare Corporation)
FDA approved a supplemental application for levetiracetam by Baxter Healthcare Corporation.
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Advanced EEG Technology in Childhood Epilepsy
A clinical trial assessing advanced EEG technology for childhood epilepsy has completed its study.
-
CLINICAL_TRIALS research · 2024-07-03Clinical Trial Update: fMRI in Deep Brain Stimulation [NA]
A clinical trial update indicates a study investigating functional MRI use in deep brain stimulation is currently recruiting for conditions …
-
CLINICAL_TRIALS research · 2024-06-24Clinical Trial Update: Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy
This entry provides a clinical trial update on a study investigating cognitive impairment in patients with drug-resistant and drug-responsiv…
-
FDA approval · 2024-06-20FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
FDA approves a supplemental application for APTIOM (eslicarbazepine acetate) submitted by Sumitomo Pharma America, Inc.
-
CLINICAL_TRIALS research · 2024-06-20Clinical Trial Update: Risk Factors and Etiologies of Epilepsy in Urban and Rural Rwanda
A completed clinical study evaluating risk factors and etiologies of epilepsy in urban and rural Rwanda.
-
FDA label_change · 2024-06-14FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for Levetiracetam from Prasco Laboratories, resulting in changes to the drug's labeling.
-
FDA approval · 2024-06-13FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for divalproex sodium from Aurobindo Pharma Limited.
-
FDA approval · 2024-06-13FDA Approved: LACOSAMIDE — Supplemental Application (Apotex Corp)
FDA approved Apotex Corp's lacosamide supplemental application under the ANDA process.
-
CLINICAL_TRIALS research · 2024-06-13Clinical Trial Update: Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome
This clinical trial is evaluating whether sulphonylureas improve neurodevelopmental outcomes in individuals with KCNJ11-related iDEND syndro…
-
FDA approval · 2024-06-13FDA Approved: TOPIRAMATE — Original Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories' original application for a generic topiramate product.
-
CLINICAL_TRIALS trial_result · 2024-06-12Clinical Trial Update: Bioequivalence Study of Perampanel Tablets 12 mg [Phase 1]
Phase 1 bioequivalence study evaluating 12 mg Perampanel tablets has been completed.
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Study on Optic Nerve Sheath Diameter Measurements in Prolonged Pediatric Seizures
A completed Balikesir University study evaluated optic nerve sheath diameter as a noninvasive marker of raised intracranial pressure in chil…
-
FDA approval · 2024-06-10FDA Approved: CLOBAZAM — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approves a supplemental application for CLOBAZAM (clobazam) submitted by Camber Pharmaceuticals, Inc. The action updates the regulatory …